Reading time: 10 minutes

Rheumatologic disease is the prototype of chronic care — rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), Sjögren’s syndrome, systemic sclerosis, and others — all requiring lifetime management. Chinese rheumatology has matured rapidly over the past two decades, and the diagnostic and treatment standards at the leading centres broadly align with international practice [1]. Access to biologic therapies (anti-TNF, anti-IL-6, anti-IL-17, JAK inhibitors, and others) at leading Chinese centres is good, and domestic biosimilars are typically priced at 30–50% of originator levels — this is the core cost advantage of considering rheumatology care in China [2]. This article works through the scenarios that justify cross-border travel, the drugs available, typical costs, and home-country handoff.

1. When Travelling to China Makes Sense for Rheumatology

The same chronic-disease principle applies: routine medication and follow-up should stay at home. The value of travelling to China is concentrated in:

  1. Unclear initial diagnosis (multiple positive autoantibodies, atypical presentation) — a second opinion from a leading centre
  2. Refractory disease (failure of multiple biologic lines) — fresh plan
  3. Drugs not promptly available at home (biologics, JAK inhibitors)
  4. Multi-organ involvement (for example, SLE with renal or central nervous system involvement) requiring multidisciplinary assessment
  5. Less common entities (IgG4-related disease, ANCA-associated vasculitis, undifferentiated connective tissue disease)
  6. Cost pressure of long-term biologic therapy — domestic biosimilars materially reduce annual treatment cost

2. Biologics and Small Molecules Available in China

Anti-TNF agents (RA / AS / psoriatic arthritis):

  1. Adalimumab (originator and several domestically approved biosimilars)
  2. Etanercept (originator and domestic alternatives)
  3. Infliximab (originator and domestic biosimilars)
  4. Golimumab
  5. Certolizumab pegol

IL-6 inhibitor: tocilizumab (originator and a domestic biosimilar) IL-17 inhibitors: secukinumab, ixekizumab IL-23 inhibitors: guselkumab, risankizumab B-cell depletion: rituximab (originator and domestic biosimilars), belimumab (for SLE), telitacicept (domestic, approved in China for SLE) JAK inhibitors: tofacitinib, baricitinib, upadacitinib, filgotinib

Domestic biosimilars are approved by the NMPA after biosimilarity studies. Indicative annual treatment cost differences (USD):

Drug Originator range at home (typical) Domestic biosimilar in China
Adalimumab 30,000–60,000 / year 4,500–8,500 / year
Infliximab 25,000–50,000 / year 3,500–7,500 / year
Rituximab (per dose) 6,000–12,000 1,500–3,000

(Originator pricing at home varies widely by insurer and country; domestic Chinese ranges are observed pricing at tertiary international departments.)

3. Disease-Specific Treatment Pathways

Rheumatoid arthritis (RA):

  1. First-line: methotrexate plus hydroxychloroquine, with low-dose steroid as needed
  2. Second-line: biologic or JAK inhibitor
  3. Leading centres include Peking Union Medical College Hospital, Peking University People’s Hospital, Renji Hospital (Shanghai), West China Hospital, and Sun Yat-sen First Hospital

Systemic lupus erythematosus (SLE):

  1. Standard: hydroxychloroquine plus steroid plus immunosuppressant (mycophenolate, cyclophosphamide, azathioprine)
  2. Newer agents: belimumab, telitacicept, anifrolumab
  3. Severe SLE with renal or CNS involvement: high-dose IV steroid plus cyclophosphamide, with plasma exchange where indicated

Ankylosing spondylitis (AS):

  1. First-line: NSAIDs plus physiotherapy
  2. Second-line: anti-TNF or IL-17 inhibitor
  3. JAK inhibitors

Sjögren’s, systemic sclerosis, vasculitis: individualised regimens requiring leading-centre evaluation

4. Hospitals to Consider

Hospital City
Peking Union Medical College Hospital, Rheumatology and Immunology Beijing
Peking University People’s Hospital, Rheumatology and Immunology Beijing
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Rheumatology and Immunology Shanghai
First Affiliated Hospital of China Medical University, Rheumatology and Immunology Shenyang
West China Hospital, Rheumatology and Immunology Chengdu
Sun Yat-sen Third Hospital, Rheumatology and Immunology Guangzhou
Xiangya Hospital, Central South University, Rheumatology and Immunology Changsha

5. Typical Process

Initial evaluation and plan optimisation (5–7 days):

  1. Days 1–2: comprehensive rheumatologic evaluation (autoantibody panel, complement, inflammatory markers, imaging)
  2. Days 3–4: biologic initiation if appropriate (subcutaneous injections in the outpatient setting)
  3. Days 5–7: response observation and discharge education

Biologic initiation (short stay):

  1. Typically 3–5 days for first-dose initiation plus safety observation

6. Typical Costs (USD, 1 USD = 6.5 RMB)

Item Public tertiary international dept. High-end private
Comprehensive rheumatologic evaluation 1,000–2,500 2,000–4,500
Rheumatology specialist consultation 100–300 200–500
Biologic initiation (with first month of drug) See table above Same + 30–50%
JAK inhibitor monthly cost 400–1,000 600–1,500
IV rituximab (single infusion) 1,500–3,000 2,500–5,000
IV cyclophosphamide pulse (single dose) 200–500 300–800

7. Handing Care Back Home

  1. Biologics prescribed in China can usually be continued at home using the same international non-proprietary name (INN) — but biosimilars from one country may not be exactly the same product as biosimilars approved in your home country, and your home-country rheumatologist will need to reassess
  2. JAK inhibitors, hydroxychloroquine, and mycophenolate are widely available at home
  3. The Chinese attending physician is typically willing to provide remote follow-up every 3–6 months

8. What MedCareInChina Can and Cannot Do on the Rheumatology Pathway

Our two products are Remote Consultation and In-China Accompanied Care.

  1. Remote Consultation: a USD 800 single-expert consultation with a rheumatologist who reviews your records and gives an initial view on plan optimisation
  2. In-China Accompanied Care: hospital accompaniment with translation through evaluation, biologic initiation, and follow-up

What we do not do: cross-border transport of biologics (subject to customs restrictions in many countries), home-country insurance liaison.

9. Action Checklist

  1. Bring 6 months of autoantibody and inflammatory marker results, imaging, and medication history
  2. Engage a remote consultation to assess scope for plan optimisation
  3. Apply for an S2 visa
  4. Plan 5–10 days in China
  5. Coordinate continuation of long-term therapy with your home-country rheumatologist before departure

Sources

[1] Chinese Rheumatology Association — Clinical guidelines for rheumatologic and immunologic disease: https://www.cra-online.org.cn/ [2] National Medical Products Administration of China — Biosimilar review records: https://www.nmpa.gov.cn/ [3] EULAR — European Alliance of Associations for Rheumatology recommendations: https://www.eular.org/ [4] ACR — American College of Rheumatology Treatment Guidelines: https://www.rheumatology.org/